Alberta Research Council Incorporated

Other

The Governors of the University of Alberta

Chembiomed, Ltd.

Richard H Smith

Glen D Armstrong

Louis D Heerze

Andre P Venot

Mohammed A Kashem

Robert M Ippolito

Kenneth R Code

Om P Srivastava

Jenny Boutros

Ahmed Moustafa

Alexander Evans

Parastoo Pourrezaei

Wasimul Haque

Roman Szweda

Daniel Jed Harrison

Pandurang V Nikrad

Ulrike Spohr

H Rizk Hanna

Cong Jiang

Per Andersson

Paul C H Li

Roderick Szarka

Wolfgang Mundt

Hossein Salimi-Moosavi

Uwe B Sleytr

Simmon C Hofstatter

Simmon Christian Hofstetter

Paul Messner

Frank M Unger

Laura Patterson-Fortin

A method and system treating aqueous effluent from an aqueous stream from at least one of a manufacturing facility, compounding facility or municipal water treatment facility. Reductive and/or oxidative chemical species in an aqueous fluid stream decompose natural hormonal or synthetic hormonal contaminants. The method includes:

Method of treatment of water effluent with multilayer filter under electric current

A method and system generate reductive and/or oxidative chemical species in an aqueous fluid stream to disinfect and/or remove contamination. A filter is provided having a filter element of at least two porous carbon support layers and a silicate wool or glass wool layer in direct contact with and between the at least two porous carbon support layers. Electric current is passed through the filter element. A fluid stream containing elemental halogens and/or halide salts is passed through the filter element, distributing halogens or halides within the filter element. contaminants from the fluid mass onto the filter element, thereby disinfecting or removing the contaminants. Oxidizing contaminants from the fluid mass are adsorbed onto the filter element, thereby disinfecting or removing the contaminants.

Method of treating contamination in a fluid stream with an electric current

Contaminants are filtered from a fluid flow stream and the filter is regenerated by a process including steps of: providing a filter material comprising both carbon and potassium iodide; passing a contaminated fluid stream in contact with the filter material; adsorbing contaminants from the fluid stream onto surfaces in the filter material; passing an electric current through the filter material with adsorbed contaminant thereon; disassociating contaminant from the surfaces of the filter material; and removing disassociated contaminant from the filter material by carrying away the disassociated contaminant in a fluid flow mass.

Electrochemical decontamination cells

This invention relates to a novel microfluidic device and methods of using this device to conduct in vitro studies on the reaction and effects of various compounds on cells. More particularly, it relates to a method for using stop flow in a microfluidic system to study the effect of compounds on individual cells. It also provides a method for observing the effects of candidate compounds on leukocyte rolling.

Microfluidic system and methods of use

This invention relates to a novel microfluidic device and methods of using this device to conduct in vitro studies on the reaction and effects of various compounds on cells. More particularly, it relates to a method for using stop flow in a microfluidic system to study the effect of compounds on individual cells.

The present invention is directed to lectin derived carbohydrate binding peptides or derivatives thereof useful for suppressing inflammatory responses, inducing tolerance to an antigen, and suppressing cell adhesion, e.g., involved in metastasis. In particular, peptides capable of binding terminally linked &agr;-sialic acid(2-6)&bgr;Gal- and/or &agr;-sialic acid(2-3)&bgr;Gal-groups on structures or molecules comprising such groups are provided. Pharmaceutical compositions containing such lectin derived carbohydrate binding peptides are also disclosed.

Anti-flammatory carbohydrate binding-peptides

The present invention is directed to methods of suppressing inflammatory responses, inducing tolerance to an antigen, and suppressing cell adhesion, e.g., involved in metastasis, by the administration of lectin derived carbohydrate binding peptides or derivatives thereof, in particular, peptides capable of binding terminally linked .alpha.-sialic acid(2.fwdarw.6).beta.Gal- and/or .alpha.-sialic acid(2.fwdarw.3).beta.Gal-groups on structures or molecules comprising such groups. Pharmaceutical compositions containing such lectin derived carbohydrate binding peptides or derivatives thereof are also disclosed.

Anti-inflammatory, tolerogenic and immunoinhibiting properties of

The present invention is directed to methods of reducing the degree of inflammation arising from a secondary immune response in a mammal due to antigen exposure (challenge) by the administration of valienamine-related disaccharide compounds and the pharmaceutical compositions employed in the method.

Administration of valienamine-related disaccharide compounds in reducing

The present invention is directed to methods of suppressing inflammatory responses, inducing tolerance to an antigen, and suppressing cell adhesion, e.g., involved in metastasis, by the administration of lectin derived carbohydrate binding peptides or derivatives thereof, in particular, peptides capable of binding terminally linked .alpha.-sialic acid(2.fwdarw.6).beta.Gal- and/or .alpha.-sialic acid(2.fwdarw.3).beta.Gal- groups on structures or molecules comprising such groups. Pharmaceutical compositions containing such lectin derived carbohydrate binding peptides or derivatives thereof are also disclosed.

The present invention is directed to methods of suppressing inflammatory responses, including tolerance to an antigen, and suppressing cell adhesion, e.g., involved in metastasis, by the administration of lectin derived carbohydrate binding peptides or derivatives thereof, in particular, peptides capable of binding terminally linked .alpha.-sialic acid (2.fwdarw.6).beta.Gal- and/or .alpha.-sialic acid(2.fwdarw.3).beta.Gal-groups on structures or molecules comprising such groups. Pharmaceutical compositions containing such lectin derived carbohydrate binding peptides or derivatives thereof are also disclosed.

Disclosed are methods for reducing the degree of antigen induced inflammation in a sensitized mammals. The disclosed methods employ oligosaccharide glycosides related to blood group determinants having a type I or type II core structure wherein the administration of such oligosaccharide glycosides is after initiation of the mammal's immune response but at or prior one-half the period of time required to effect maximal antigen-induced inflammation.

Time dependent administration of oligosaccharide glycosides related to

Disclosed are novel Lewis.sup.x and Lewis.sup.a analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.

Immunosuppressive and tolerogenic modified Lewis.sup.x compounds

Monofucosylated and monosialyated derivatives of the compound .beta.Gal(1-4).beta.GlcNAc(1-3).beta.Gal(1-4).beta.GlcNAc-OR, where R is hydrogen, a saccharide, an oligosaccharide or an aglycon moiety have been found to be useful in modulating a cell-mediated immune inflammatory response in mammals.

Methods for the synthesis of monofucosylated oligosaccharides

The invention is directed to a lectin derived carbohydrate binding-peptide which inhibits cell-mediated immune responses and has the amino acid sequence SPYGRC. The peptide binds terminally linked .alpha.-sialic acid (2.fwdarw.3).beta.Gal- and .alpha.-sialic (2.fwdarw.6).beta.Gal-structures and is a acid fragment of the S2 subunit of pertussis toxin produced by Bordetella pertussis.

Growing community of inventors

Edmonton, Canada

Richard H Smith